---
input_text: 'Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes
  in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. Importance:
  Although effective agents are available to prevent painful vaso-occlusive episodes
  of sickle cell disease (SCD), there are no disease-modifying therapies for ongoing
  painful vaso-occlusive episodes; treatment remains supportive. A previous phase
  3 trial of poloxamer 188 reported shortened duration of painful vaso-occlusive episodes
  in SCD, particularly in children and participants treated with hydroxyurea. Objective:
  To reassess the efficacy of poloxamer 188 for vaso-occlusive episodes. Design, Setting,
  and Participants: Phase 3, randomized, double-blind, placebo-controlled, multicenter,
  international trial conducted from May 2013 to February 2016 that included 66 hospitals
  in 12 countries and 60 cities; 388 individuals with SCD (hemoglobin SS, SC, S-beta0
  thalassemia, or S-beta+ thalassemia disease) aged 4 to 65 years with acute moderate
  to severe pain typical of painful vaso-occlusive episodes requiring hospitalization
  were included. Interventions: A 1-hour 100-mg/kg loading dose of poloxamer 188 intravenously
  followed by a 12-hour to 48-hour 30-mg/kg/h continuous infusion (n = 194) or placebo
  (n = 194). Main Outcomes and Measures: Time in hours from randomization to the last
  dose of parenteral opioids among all participants and among those younger than 16
  years as a separate subgroup. Results: Of 437 participants assessed for eligibility,
  388 were randomized (mean age, 15.2 years; 176 [45.4%] female), the primary outcome
  was available for 384 (99.0%), 15-day follow-up contacts were available for 357
  (92.0%), and 30-day follow-up contacts were available for 368 (94.8%). There was
  no significant difference between the groups for the mean time to last dose of parenteral
  opioids (81.8 h for the poloxamer 188 group vs 77.8 h for the placebo group; difference,
  4.0 h [95% CI, -7.8 to 15.7]; geometric mean ratio, 1.2 [95% CI, 1.0-1.5]; P = .09).
  Based on a significant interaction of age and treatment (P = .01), there was a treatment
  difference in time from randomization to last administration of parenteral opioids
  for participants younger than 16 years (88.7 h in the poloxamer 188 group vs 71.9
  h in the placebo group; difference, 16.8 h [95% CI, 1.7-32.0]; geometric mean ratio,
  1.4 [95% CI, 1.1-1.8]; P = .008). Adverse events that were more common in the poloxamer
  188 group than the placebo group included hyperbilirubinemia (12.7% vs 5.2%); those
  more common in the placebo group included hypoxia (12.0% vs 5.3%). Conclusions and
  Relevance: Among children and adults with SCD, poloxamer 188 did not significantly
  shorten time to last dose of parenteral opioids during vaso-occlusive episodes.
  These findings do not support the use of poloxamer 188 for vaso-occlusive episodes.
  Trial Registration: ClinicalTrials.gov Identifier: NCT01737814.'
raw_completion_output: |-
  primary_disease: Sickle Cell Disease (SCD)

  medical_actions: intravenous administration of poloxamer 188; administration of placebo; hospitalization; administration of parenteral opioids

  symptoms: painful vaso-occlusive episodes; acute moderate to severe pain; hyperbilirubinemia; hypoxia

  chemicals: poloxamer 188; hydroxyurea; opioids

  action_annotation_relationships: intravenous administration of poloxamer 188 TREATS painful vaso-occlusive episodes IN Sickle Cell Disease (SCD); administration of parenteral opioids TREATS acute moderate to severe pain IN Sickle Cell Disease (SCD); intravenous administration of poloxamer 188 PREVENTS acute moderate to severe pain IN Sickle Cell Disease (SCD); hospitalization TREATS painful vaso-occlusive episodes IN Sickle Cell Disease (SCD); administration of hydroxyurea PREVENTS painful vaso-occlusive episodes IN Sickle Cell Disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  administration of hydroxyurea PREVENTS painful vaso-occlusive episodes IN Sickle Cell Disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - intravenous administration of poloxamer 188
    - administration of placebo
    - hospitalization
    - administration of parenteral opioids
  symptoms:
    - painful vaso-occlusive episodes
    - acute moderate to severe pain
    - HP:0002904
    - HP:0012418
  chemicals:
    - CHEBI:32026
    - CHEBI:44423
    - opioids
  action_annotation_relationships:
    - subject: intravenous administration
      predicate: TREATS
      object: painful vaso-occlusive episodes
      qualifier: MONDO:0007374
      subject_extension: CHEBI:32026
    - subject: administration of parenteral opioids
      predicate: TREATS
      object: acute moderate to severe pain
      qualifier: MONDO:0007374
      subject_qualifier: parenteral
      subject_extension: opioids
    - subject: intravenous administration
      predicate: PREVENTS
      object: HP:0012531
      qualifier: MONDO:0007374
      subject_extension: CHEBI:32026
      object_extension: acute moderate to severe
    - subject: <hospitalization>
      predicate: <TREATS>
      object: <painful vaso-occlusive episodes>
      qualifier: MONDO:0007374
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: administration of hydroxyurea
      predicate: PREVENTS
      object: painful vaso-occlusive episodes
      qualifier: MONDO:0007374
      subject_extension: CHEBI:44423
named_entities:
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: MAXO:0000457
    label: Pain Management
  - id: HP:0012531
    label: Pain
  - id: HP:0000739
    label: anxiety
  - id: MONDO:0005812
    label: Influenza
  - id: MAXO:0001017
    label: vaccination
  - id: MAXO:0000756
    label: transfusion
  - id: MONDO:0018881
    label: Myelodysplasia
  - id: MONDO:0000984
    label: Thalassemia
  - id: MONDO:0018373
    label: avascular necrosis (AVN)
  - id: MAXO:0009047
    label: total hip replacement (THR)
  - id: HP:0010885
    label: avascular necrosis
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: CHEBI:131923
    label: Salubrinal
  - id: MAXO:0000068
    label: Transplantation
  - id: CHEBI:44423
    label: hydroxyurea
  - id: MONDO:0003664
    label: Haemolytic Anaemias
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0025464
    label: Oxidative stress
  - id: MAXO:0001298
    label: therapies
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: Arginine
  - id: CHEBI:18211
    label: Citrulline
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:50733
    label: Nutritional supplements
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0000716
    label: Depression
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplant (HSCT)
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0035088
    label: magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA)
  - id: HP:0002140
    label: ischemic stroke
  - id: HP:0001139
    label: abnormal transcranial Doppler ultrasound (TCD) results
  - id: MONDO:0006079
    label: Acute Chest Syndrome (ACS)
  - id: HP:0001945
    label: Fever
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:82594
    label: Ferritin
  - id: HP:0002204
    label: pulmonary embolism
  - id: CHEBI:50249
    label: anticoagulants
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:82557
    label: treosulfan
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: CHEBI:63895
    label: Interleukin (IL)-6
  - id: CHEBI:197439
    label: TNFalpha
  - id: MONDO:0005502
    label: Dengue fever
  - id: HP:0003326
    label: myalgia
  - id: HP:0002027
    label: abdominal pain
  - id: HP:0002315
    label: headache
  - id: CHEBI:18050
    label: L-glutamine
  - id: MONDO:0018948
    label: Moyamoya disorder (MMD)
  - id: HP:0001250
    label: seizures
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: CHEBI:28876
    label: melphalan
  - id: CHEBI:61049
    label: tacrolimus
  - id: CHEBI:44185
    label: methotrexate
  - id: MAXO:0000004
    label: Surgical intervention
  - id: CHEBI:16335
    label: Adenosine
  - id: CHEBI:177467
    label: Opiorphin
  - id: CHEBI:17347
    label: Testosterone
  - id: MAXO:0000149
    label: hematopoietic cell transplantation (HCT)
  - id: HP:0001297
    label: Stroke
  - id: MONDO:0005151
    label: Endocrinopathy
  - id: HP:0004322
    label: short stature
  - id: HP:0000819
    label: diabetes mellitus
  - id: HP:0000135
    label: hypogonadism
  - id: HP:0000938
    label: osteopenia
  - id: HP:0000939
    label: osteoporosis
  - id: HP:0000821
    label: hypothyroidism
  - id: HP:0008163
    label: hypocortisolism
  - id: HP:0000829
    label: hypoparathyroidism
  - id: HP:0000818
    label: Endocrinopathy
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: MONDO:0013730
    label: Acute Graft-versus-Host Disease (GVHD)
  - id: HP:0001903
    label: anemia
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0000083
    label: Kidney failure
  - id: HP:0002617
    label: Vasculopathy
  - id: CHEBI:17303
    label: Morphine
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0031417
    label: rhinorrhea
  - id: HP:0012735
    label: cough
  - id: HP:0025095
    label: sneezing
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:5588
    label: Hemoglobin A (HbA)
  - id: MAXO:0000602
    label: hemodialysis
  - id: HP:0011675
    label: Arrhythmias
  - id: HP:0012418
    label: Hypoxia
  - id: HP:0001907
    label: thromboembolism
  - id: CHEBI:114786
    label: Sodium metabisulphite
  - id: CHEBI:17790
    label: Methanol
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:59229
    label: GnRH antagonist
  - id: CHEBI:63533
    label: GnRH agonist
  - id: MAXO:0001490
    label: platelet transfusions
  - id: CHEBI:9168
    label: sirolimus
  - id: MAXO:0009003
    label: Preimplantation genetic testing
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0100602
    label: Preeclampsia
  - id: HP:0001622
    label: Preterm birth
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0100806
    label: Sepsis
  - id: CHEBI:41879
    label: Dexamethasone
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: HP:0001878
    label: Hemolytic anemia
  - id: HP:0002904
    label: hyperbilirubinemia
  - id: CHEBI:32026
    label: poloxamer 188
